Insider Buying: Cooper Companies (NASDAQ:COO) Director Buys $378,770.00 in Stock

The Cooper Companies, Inc. (NASDAQ:COO) Director Walter Rosebrough, Jr. bought 7,000 shares of the stock in a transaction dated Friday, September 11th. The shares were purchased at an average cost of $54.11 per share, for a total transaction of $378,770.00. Following the completion of the purchase, the director owned 17,000 shares in the company, valued at approximately $919,870. This represents a 70.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Cooper Companies Price Performance

Shares of Cooper Companies stock opened at $53.78 on Friday. The company has a quick ratio of 0.73, a current ratio of 1.22 and a debt-to-equity ratio of 0.23. The Cooper Companies, Inc. has a twelve month low of $51.01 and a twelve month high of $89.83. The business has a 50-day moving average price of $70.23 and a 200 day moving average price of $68.77. The firm has a market cap of $10.23 billion, a PE ratio of 18.35, a P/E/G ratio of 2.22 and a beta of 0.82.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.12 by $0.03. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%.The company had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.10 billion. During the same quarter in the prior year, the business posted $0.49 earnings per share. Cooper Companies’s revenue for the quarter was up .5% on a year-over-year basis. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Sell-side analysts predict that The Cooper Companies, Inc. will post 4.53 earnings per share for the current fiscal year.

Cooper Companies declared that its board has initiated a stock buyback plan on Wednesday, September 9th that authorizes the company to buyback $3.00 billion in outstanding shares. This buyback authorization authorizes the medical device company to purchase up to 22.7% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.

Hedge Funds Weigh In On Cooper Companies

Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in shares of Cooper Companies in the second quarter valued at approximately $1,077,762,000. Generation Investment Management LLP acquired a new position in Cooper Companies during the second quarter worth $356,304,000. Jupiter Topco LLC acquired a new position in Cooper Companies during the second quarter worth $305,074,000. Diamond Hill Capital Management Inc. grew its holdings in Cooper Companies by 479.6% in the 4th quarter. Diamond Hill Capital Management Inc. now owns 3,287,837 shares of the medical device company’s stock valued at $269,471,000 after buying an additional 2,720,594 shares in the last quarter. Finally, Franklin Resources Inc. increased its stake in shares of Cooper Companies by 108.2% in the 4th quarter. Franklin Resources Inc. now owns 4,022,033 shares of the medical device company’s stock worth $329,646,000 after acquiring an additional 2,089,763 shares during the last quarter. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

COO has been the subject of a number of research reports. Wall Street Zen cut shares of Cooper Companies from a “buy” rating to a “hold” rating in a research note on Saturday, September 12th. Wells Fargo & Company set a $61.00 price objective on Cooper Companies and gave the stock an “equal weight” rating in a report on Thursday, September 10th. The Goldman Sachs Group set a $61.00 price objective on Cooper Companies in a research note on Wednesday, May 27th. UBS Group decreased their target price on Cooper Companies from $75.00 to $66.00 and set a “neutral” rating on the stock in a research report on Thursday, September 10th. Finally, KeyCorp reaffirmed a “sector weight” rating on shares of Cooper Companies in a research note on Friday, June 5th. Five analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $71.47.

Key Stories Impacting Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Director Lawrence Kurzius purchased 10,000 shares for approximately $549,300, increasing his position by 47.4%. Other directors, including Paul Keel and Walter Rosebrough Jr., also recently bought shares. The purchases may provide a modest confidence signal from insiders after the selloff. Insider purchase report
• Neutral Sentiment: Jana Partners is pressing Cooper to replace its chief executive and pursue an urgent overhaul, citing “chronic underperformance.” The activist campaign could create a catalyst for strategic change, but it also increases leadership and execution uncertainty. Wall Street Journal activist report
• Negative Sentiment: Cooper’s latest quarterly results beat adjusted EPS expectations, $1.15 versus $1.12, but revenue of approximately $1.07 billion missed the $1.10 billion consensus. Management also reduced fiscal 2026 adjusted EPS guidance to $4.51–$4.55 and revenue guidance to $4.23–$4.25 billion, reflecting weaker contact-lens demand.
• Negative Sentiment: Reports that U.S. distributors are reducing channel inventories have raised concerns about near-term sales and whether the weakness reflects temporary destocking or softer underlying demand. Inventory destocking report
• Negative Sentiment: Pomerantz, Bragar Eagel & Squire, and Levi & Korsinsky announced investigations into potential securities claims. These notices do not establish wrongdoing, but they add legal and headline risk. Analysts have also lowered their consensus price target to about $72.27. Pomerantz investigation

About Cooper Companies

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.